As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies.
Please note that following on from information received from the company, this appraisal has been rescheduled into the work programme.
We now anticipate that the appraisal will begin during mid-January 2023 when we will write to you about how you can get involved.